Julian Baker’s Vor Biopharma VOR Stock Holding History

Julian Baker’s Portfolio VOR Stock Details VOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-31,692	Closed	-$1.34M	–	101
2023 Q3	$1.34M	Hold	31,692	–	–	0.01%	94
2023 Q2	$1.96M	Hold	31,692	–	–	0.01%	97
2023 Q1	$3.41M	Sell	31,692 -41,604	-57%	-$4.61M	0.02%	80
2022 Q4	$9.75M	Hold	73,296	–	–	0.06%	59
2022 Q3	$5.83M	Buy	73,296 +16,358	+29%	+$1.61M	0.04%	73
2022 Q2	$5.66M	Buy	+56,938	New	+$5.83M	0.03%	78

Other funds holding VOR

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Julian Baker's VOR Position: Q4 2023 in Review

Julian Baker sold out of Vor Biopharma (VOR) in Q4 2023, closing a stake of 31,692 shares — an estimated $1.34M sold.

Julian Baker first reported a position in VOR in Q2 2022 and held it in 6 quarters. The position peaked at $9.75M in Q4 2022. 60 funds tracked by Wall St. Rank hold VOR as of Q4 2023.

Julian Baker reported no remaining Vor Biopharma position as of Q4 2023 after selling out during the quarter.
Julian Baker sold 31,692 Vor Biopharma shares in Q4 2023, an estimated $1.34M.
Julian Baker first reported a position in Vor Biopharma in Q2 2022 and held it in 6 quarters.
Julian Baker's Vor Biopharma position peaked at $9.75M in Q4 2022.
60 funds tracked by Wall St. Rank held Vor Biopharma as of Q4 2023.

Based on Baker Bros. Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.